2667-0895

Atherosclerosis Plus

Elsevier

View prefix report (10.1016)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 288 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact288 DOIs
2

Attach ORCID iDs across 156 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact156 DOIs
3

Deposit reference lists for 124 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Medium impact124 DOIs

DOIs for this ISSN

Showing the top 5 of 288 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 HDL and chronic kidney disease (10.1016/j.athplu.2023.04.001)
Abstract ORCID
74.57 30
2 Executive summary of the Hellenic Atherosclerosis Society gu… (10.1016/j.athplu.2024.01.004)
Abstract ORCID
69.01 23
3 How many FH genetic tests were performed by the UK Genetic L… (10.1016/j.athplu.2023.07.005)
Abstract References ORCID
58.36 5
4 Prediabetes is an incremental risk factor for adverse cardia… (10.1016/j.athplu.2023.08.002)
Abstract ORCID
57.31 13
5 Anti-atherosclerotic effects of natural compounds targeting… (10.1016/j.athplu.2024.12.004)
Abstract ORCID
53.96 11
6 Periostin contributes to the adventitial remodeling of ather… (10.1016/j.athplu.2022.10.001)
Abstract ORCID
52.07 10
7 Association between Helicobacter pylori infection and caroti… (10.1016/j.athplu.2021.08.004)
Abstract ORCID
50.00 9
8 Plasma lipids in Pseudoxanthoma Elasticum (PXE) patients: A… (10.1016/j.athplu.2023.12.003)
Abstract ORCID
45.15 7
9 Acute myocardial infarction preferentially alters low-abunda… (10.1016/j.athplu.2023.12.001)
Abstract ORCID
42.25 6
10 Glucagon-like Peptide-1 analogues and delipidation of corona… (10.1016/j.athplu.2024.03.001)
Abstract ORCID
42.25 6
11 Evaluation of contemporary treatment of high- and very high-… (10.1016/j.athplu.2021.08.003)
Abstract
39.78 38
12 Fucosterol exerts an anti-atherosclerotic action via NF-κB a… (10.1016/j.athplu.2025.05.001)
Abstract ORCID
38.91 5
13 Lipoprotein(a), Interleukin-6 inhibitors, and atheroscleroti… (10.1016/j.athplu.2023.09.001)
Abstract
38.29 33
14 High-density lipoproteins and non-alcoholic fatty liver dise… (10.1016/j.athplu.2023.08.001)
Abstract
36.93 29
15 Young women with familial hypercholesterolemia have higher L… (10.1016/j.athplu.2023.01.001)
Abstract
35.78 26
16 Variants in LPA are associated with mutation-negative Famili… (10.1016/j.athplu.2024.08.015)
Abstract References ORCID
35.78 2
17 Smad2 inhibition of MET transcription potentiates human vasc… (10.1016/j.athplu.2021.08.005)
Abstract ORCID
34.95 4
18 Lp(a) does not affect intima media thickness in hypercholest… (10.1016/j.athplu.2022.11.001)
Abstract ORCID
34.95 4
19 “Inclisiran: Early LDL-C target achievement in a real-life p… (10.1016/j.athplu.2025.01.001)
Abstract ORCID
34.95 4
20 The association between dolutegravir based first-line antire… (10.1016/j.athplu.2025.08.001)
Abstract ORCID
34.95 4
21 High-density lipoprotein cholesterol: A marker of COVID-19 i… (10.1016/j.athplu.2021.08.007)
Abstract
34.51 23
22 Emerging oral therapeutic strategies for inhibiting PCSK9 (10.1016/j.athplu.2024.11.003)
Abstract
33.56 21
23 NAD+ metabolism and therapeutic strategies in cardiovascular… (10.1016/j.athplu.2024.06.001)
Abstract
31.97 18
24 Endothelial dysfunction and cardiovascular diseases in peopl… (10.1016/j.athplu.2024.01.003)
Abstract
30.76 16
25 Impact of atherosclerotic extent on clinical outcome for dia… (10.1016/j.athplu.2021.07.021)
Abstract ORCID
30.10 3
26 Cholesterol efflux promoting function of high-density lipopr… (10.1016/j.athplu.2021.08.002)
Abstract ORCID
30.10 3
27 Lipids, lipoproteins and prevalence of familial hypercholest… (10.1016/j.athplu.2022.03.004)
Abstract ORCID
30.10 3
28 Semaglutide treatment attenuates vessel remodelling in ApoE−… (10.1016/j.athplu.2022.05.004)
Abstract
30.10 15
29 Low-density lipoprotein cholesterol goal attainment in Germa… (10.1016/j.athplu.2022.07.024)
Abstract
30.10 15
30 Dendritic cell marker Clec4a4 deficiency limits atherosclero… (10.1016/j.athplu.2022.12.001)
Abstract ORCID
30.10 3
31 Treatment intensification with bempedoic acid to achieve LDL… (10.1016/j.athplu.2024.01.006)
Abstract ORCID
30.10 3
32 Inclisiran for fast-track lipid-lowering treatment early aft… (10.1016/j.athplu.2025.09.005)
Abstract ORCID
30.10 3
33 Colchicine reduces atherosclerotic plaque vulnerability in r… (10.1016/j.athplu.2021.08.008)
Abstract
29.40 14
34 Effectiveness and safety of PCSK9 inhibitors in real-world c… (10.1016/j.athplu.2021.08.009)
Abstract
29.40 14
35 Low HDL-c levels at admission are associated with greater se… (10.1016/j.athplu.2023.01.002)
Abstract
29.40 14
36 Clinical characteristics and cardiovascular outcomes among y… (10.1016/j.athplu.2022.08.003)
Abstract
28.65 13
37 Utilization of IVUS improves all-cause mortality in patients… (10.1016/j.athplu.2021.07.001)
Abstract
27.85 12
38 Principal predictors of major adverse limb events in diabeti… (10.1016/j.athplu.2021.10.003)
Abstract
27.85 12
39 Smoking and diabetes attenuate beneficial effects of PSCK9 i… (10.1016/j.athplu.2022.07.001)
Abstract
27.85 12
40 Familial hypercholesterolemia and COVID-19: A menacing but t… (10.1016/j.athplu.2021.08.001)
Abstract
26.98 11
41 Associations of very low Lipoprotein(a) levels with risks of… (10.1016/j.athplu.2024.07.001)
Abstract
26.98 11
42 Lipoprotein(a) and the atherosclerotic burden – Should we wa… (10.1016/j.athplu.2024.09.004)
Abstract
26.98 11
43 Assessment of plasma ceramides as predictor for subclinical… (10.1016/j.athplu.2021.09.005)
Abstract
26.03 10
44 Atherosclerosis severity in patients with familial hyperchol… (10.1016/j.athplu.2022.03.002)
Abstract
26.03 10
45 Estimated cardiovascular benefits of bempedoic acid in patie… (10.1016/j.athplu.2022.05.003)
Abstract
26.03 10
46 Lomitapide does not alter PCSK9 and Lp(a) levels in homozygo… (10.1016/j.athplu.2021.05.001)
Abstract
25.00 9
47 High baseline fetuin-A levels are associated with lower athe… (10.1016/j.athplu.2021.09.001)
Abstract
25.00 9
48 Age dependent association between remnant cholesterol and ca… (10.1016/j.athplu.2021.09.004)
Abstract
25.00 9
49 Hypoglycemia-induced changes in complement pathways in type… (10.1016/j.athplu.2021.11.002)
Abstract
25.00 9
50 Polygenic risk score for hypercholesterolemia in a Brazilian… (10.1016/j.athplu.2022.06.002)
Abstract
25.00 9